Publication: Lymphatic blood filling in CLEC-2-deficient mouse models
Issued Date
2020-01-01
Resource Type
ISSN
13691635
09537104
09537104
Other identifier(s)
2-s2.0-85081231036
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Platelets. (2020)
Suggested Citation
Elizabeth J. Haining, Kate L. Lowe, Surasak Wichaiyo, Raghu P. Kataru, Zoltan Nagy, Dean Pj Kavanagh, Sian Lax, Ying Di, Bernhard Nieswandt, Benoît Ho-Tin-Noé, Babak J. Mehrara, Yotis A. Senis, Julie Rayes, Steve P. Watson Lymphatic blood filling in CLEC-2-deficient mouse models. Platelets. (2020). doi:10.1080/09537104.2020.1734784 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/53879
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Lymphatic blood filling in CLEC-2-deficient mouse models
Abstract
© 2020, © 2020 Taylor & Francis Group, LLC. C-type lectin-like receptor 2 (CLEC-2) is considered as a potential drug target in settings of wound healing, inflammation, and infection. A potential barrier to this is evidence that CLEC-2 and its ligand podoplanin play a critical role in preventing lymphatic vessel blood filling in mice throughout life. In this study, this aspect of CLEC-2/podoplanin function is investigated in more detail using new and established mouse models of CLEC-2 and podoplanin deficiency, and models of acute and chronic vascular remodeling. We report that CLEC-2 expression on platelets is not required to maintain a barrier between the blood and lymphatic systems in unchallenged mice, post-development. However, under certain conditions of chronic vascular remodeling, such as during tumorigenesis, deficiency in CLEC-2 can lead to lymphatic vessel blood filling. These data provide a new understanding of the function of CLEC-2 in adult mice and confirm the essential nature of CLEC-2-driven platelet activation in vascular developmental programs. This work expands our understanding of how lymphatic blood filling is prevented by CLEC-2-dependent platelet function and provides a context for the development of safe targeting strategies for CLEC-2 and podoplanin.